A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis
Open Access
- 22 January 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1719899
Abstract
Purpose: To evaluate the predictors and prognostic impact of sarcopenic obesity (Sa-O) on all-cause mortality in patients with cirrhosis. Methods: This retrospective cohort study included cirrhosis patients. Sa-O was defined using computed tomography at L3 level as a skeletal muscle index 2 /m 2 or 100 cm 2 . The primary outcome was all-cause mortality. A nomograph was developed based on identified predictors, generating the age–body mass index (BMI)–alcohol–hypertension (ABAH) score. Results: Among 769 cirrhosis patients (60.1% male; 45.5% aged ≥60 years; median follow-up: 4.3 [1.7–7.0] years), 129 (16.8%) were diagnosed with Sa-O. Multivariable analysis identified age (OR [odds ratio] 1.813, 95% confidence interval [CI] 1.210–2.718, p = 0.0040), BMI ≥ 28 kg/m 2 (OR 0.076, 95% CI 0.018–0.317, p = 0.0011), alcoholic liver disease (OR 1.685, 95% CI 1.078–2.634, p = 0.0220), and hypertension (OR 1.801, 95% CI 1.184–2.739, p = 0.0059) as independent predictors of Sa-O. As for BMI (OR 0.076), the limitations of BMI in reflecting body composition led to the counterintuitive research findings. When stratified by ABAH score into low (p = 0.026). The prognostic value of the ABAH score was analyzed using a Cox proportional hazards model by subgroups analysis. It showed significant prognostic value for all-cause mortality, with medium-score patients exhibiting a 1.53-fold increased risk (95% CI 1.12–2.09, p = 0.007) and high-score patients a 1.72-fold increased risk (95% CI 1.22–2.42, p = 0.002) compared to the low-score reference group. Conclusion: Sa-O in patients with cirrhosis is associated with age, BMI, alcoholic liver disease, and hypertension. The newly developed ABAH score, a composite clinical risk marker, predicted the probability of Sa-O and was associated with all-cause mortality in patients with cirrhosis.Keywords
Funding Information
- Peking University Hepatology Institute Qi-Min Project
- National Natural Science Foundation of China (82304215)
- Peking University People’s Hospital Scientific Research Development Funds (RS2024-06)
- Peking University People’s Hospital Scientific Research Development Funds (RDL2024-06)
This publication has 28 references indexed in Scilit:
- Sarcopenia and Sarcopenic Obesity and Mortality Among Older PeopleJAMA Network Open, 2024
- Obesity Paradox: Fact or Fiction?Current Obesity Reports, 2023
- Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysisJournal of Hepatology, 2022
- Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseasesHepatology, 2021
- Sarcopenia and frailty in decompensated cirrhosisJournal of Hepatology, 2021
- ICD-11The Lancet, 2019
- SarcopeniaThe Lancet, 2019
- Burden of liver diseases in the worldJournal of Hepatology, 2019
- EASL Clinical Practice Guidelines on nutrition in chronic liver diseaseJournal of Hepatology, 2019
- Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosisJournal of Cachexia, Sarcopenia and Muscle, 2015